Press Releases June 2, 2026 07:00 AM

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference

Bioventus CFO to participate in Goldman Sachs 47th Annual Global Healthcare Conference

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BVS

Bioventus Inc. announced that CFO Mark Singleton will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The company, a leader in active healing innovations, will webcast the presentation live and replay it for investors. Bioventus focuses on products for pain treatment, restorative therapies, and surgical solutions.

Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
BVS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CFO Mark Singleton to engage in a high-profile healthcare conference fireside chat, providing investor insights.
  • Bioventus continues to highlight its leadership in active healing with a focus on pain treatment, restorative therapies, and surgical solutions.
  • The live webcast and replay offer transparency and engagement opportunities for investors.

DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.m. ET.

A live webcast of the presentation will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Contact:
Dave Crawford
919-474-6787
[email protected]


Risks

  • Market reaction to the conference presentation is uncertain and depends on the details disclosed.
  • Bioventus operates in the competitive healthcare innovation sector, which is subject to regulatory and reimbursement challenges.
  • Dependence on continued clinical efficacy and cost-effectiveness to maintain market position.

More from Press Releases

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Sep 3, 2026 Tenable Uses OpenAI GPT Cyber Models to Help Defenders Inspect Community-Built AI Components Sep 3, 2026 XTEND Reality Expansion Ltd. and JFB Construction Holdings Complete Business Combination, Raising $110 Million in Total Capital Sep 3, 2026 Freshworks Announces Inducement Grant under Listing Rule 5635(C)(4) of the Nasdaq Stock Market Sep 3, 2026 Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS Sep 3, 2026